Cassava Sciences saw a welcome improvement to its Relative Strength (RS) Rating on Wednesday, with an upgrade from 79 to 88. After 3 positive days, the stock has taken a breather today, as of this writing.
As you try to find the best stocks to buy and watch, be sure to pay attention to relative price strength.
IBD's unique rating identifies market leadership with a 1 (worst) to 99 (best) score. The rating shows how a stock's price behavior over the last 52 weeks compares to all the other stocks in our database.
Over 100 years of market history reveals that the best stocks often have an RS Rating north of 80 as they begin their biggest climbs.
See How IBD Helps You Make More Money In Stocks
The stock is currently not in an ideal buy zone. Look for the stock to create a new chance to pick up shares like a three-weeks tight or pullback to the 50-day or 10-week moving average.
SAVA Earnings
The company showed 0% earnings growth in its most recent report, while sales growth came in at 0%.
The company earns the No. 172 rank among its peers in the Medical-Biomed/Biotech industry group. Neurocrine Biosciences and Immunogen are also among the group's highest-rated stocks.
Stocks To Buy And Watch: Top IPOs, Big And Small Caps, Growth Stocks
